GLP-1 medications such as Ozempic, Wegovy and Rybelsus are best known for helping people lose weight, steady blood sugar and cut cardiovascular risk. A new clinical trial suggests they may do something more fundamental: slow some of the molecular processes tied to aging.
Published in Nature Communications, the study gives the first randomized, placebo-controlled human evidence that semaglutide — the shared active ingredient in those drugs — may slow the accumulation of DNA markers linked to biological aging. The work came from the University of California San Diego and collaborators.
The team drew on an earlier trial of 108 adults with HIV-associated lipohypertrophy, a condition that pools excess fat around the abdomen. Roughly half received weekly semaglutide injections; the rest got a placebo. To gauge aging, the researchers used "epigenetic clocks" — tools that estimate biological age from DNA methylation, the pattern of chemical tags that switches genes on or off without altering the DNA sequence itself.
Adults living with HIV often show accelerated biological aging because of chronic inflammation, even when the virus is well controlled. The findings hint that semaglutide may counter some effects of that inflammation across several organ systems. The authors stress the result is an early signal from a specific population, not proof of anti-aging benefit for the general public, and larger trials are planned.
Knowledge takeaway: in a randomized, placebo-controlled trial, semaglutide slowed epigenetic-clock markers of biological aging in adults with HIV; this is the first randomized human evidence that GLP-1 drugs may influence aging biology, though confirmation in broader populations is still needed.